This study was designed to compare usnic acid with anti-breast cancer drug molecules (A-BCDM) routinely used in the treatment of breast cancer. The miRNA information of 17 anti-breast cancer drug used in breast cancer treatment was obtained from the Small Molecule-miRNA Network-Based Inferance (SMIR-NBI) tool. We had been determined common and different expressed miRNAs between 17 A-BCDM & usnic acid and were classified according to the common miRNAs to reveal molecular similarity. As a result of the bioinformatic analyzes, 20 common miRNAs were determined between 17 A-BCDM and usnic acid. The common miRNAs were analyzed with bioinformatic tolls for determining pathways and targets. The most common miRNAs for 6 of 17 A-BCDM and usnic acid were determined as miR-374a-5p and miR-26a-5p. We compared the anti-proliferative effect of usnic acid and one of the 17 A-BCDM that tamoxifen on MDA-MB-231 triple negative breast cancer cell with real-time cell analysis system. The real time PCR assay was carried out with miR-26a-5p for evaluate to expression level of MDA-MB-231 breast cancer cell and MCF-12A non-cancerous epithelial breast cell. As a result of study, usnic acid as novel candidate drug molecule showed high similarity ratio with 5-Fluorouracil, Sulindac Sulfide, Curcumin and Cisplatin A-BCDM used in treatment of breast cancer. miR-26a-5p as common response miRNA of usnic acid and tamoxifen was showed a decreased level of expression by validated qRT-PCR assay. The obtained from study, in addition to 17 A-BCDM, usnic acid has also the potential to be used as a candidate molecule in the treatment of breast cancer. Moreover, miR-26a-5p might be used as a biomarker in the treatment of breast cancer but further analysis is required.

本研究旨在将松萝酸与常规用于治疗乳腺癌的抗乳腺癌药物分子 (A-BCDM) 进行比较。用于乳腺癌治疗的17种抗乳腺癌药物的miRNA信息来自Small Molecule-miRNA Network-Based Inferance (SMIR-NBI)工具。我们已经确定了 17 A-BCDM 和松萝酸之间常见和不同表达的 miRNA，并根据常见的 miRNA 进行分类以揭示分子相似性。作为生物信息学分析的结果，在 17 A-BCDM 和松萝酸之间确定了 20 种常见的 miRNA。使用生物信息学收费分析常见的 miRNA 以确定途径和目标。17 种 A-BCDM 和松萝酸中的 6 种最常见的 miRNA 被确定为 miR-374a-5p 和 miR-26a-5p。我们用实时细胞分析系统比较了松萝酸和他莫昔芬的 17 A-BCDM 之一对 MDA-MB-231 三阴性乳腺癌细胞的抗增殖作用。使用miR-26a-5p进行实时PCR测定以评估MDA-MB-231乳腺癌细胞和MCF-12A非癌性上皮乳腺细胞的表达水平。研究结果表明，松萝酸作为新型候选药物分子与用于治疗乳腺癌的 5-氟尿嘧啶、苏林酸硫化物、姜黄素和顺铂 A-BCDM 显示出高相似率。miR-26a-5p 作为松萝酸和他莫昔芬的常见反应 miRNA，经验证的 qRT-PCR 测定显示表达水平降低。研究结果表明，除了 17 A-BCDM 外，松萝酸还有可能作为候选分子用于治疗乳腺癌。而且，